Medivir’s CEO: “There is an obvious need for fostrox”

Medivir has gone through an eventful period, marked by the presentation of clinical results at ESMO and a new collaboration agreement with pharmaceutical giant Eisai. The next target is a randomized phase IIb study to enable breakthrough therapy designation and accelerated approval process. CEO Jens Lindberg notes that these recent developments have strengthened fostrox’s potential to become the first approved treatment for second-line liver cancer.

Read the article at biostock.se:

https://www.biostock.se/en/2024/11/medivirs-ceo-there-is-an-obvious-need-for-fostrox/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/